YB Urban Renewal Residential Development Ltd, formerly known as Cannassure Therapeutics Ltd, is an Israel-based urban renewal company. The Company is engaged mainly in urban renewal projects. In the urban renewal projects sector, the Company partakes in activities that aim to clear out areas of inner cities deemed to be neglected, unused and loosely maintained, in favor of new multifamily housing, business areas, as well as other developments improving the city landscape. The Firm aims to achieve economic, cultural and environmental renewal of the neglected inner city areas. The Company cooperates with a range of specialists in the field of urban renewal with knowledge and experience in urban planning and construction work.

Employees

Sector

Real Estate Development & Operations

More about the company

Market Cap	3.21Cr 1.08Cr 94.34L 87.26L 81.45L 1.53Cr 102.03Cr 1.54Cr 10Cr 4.03Cr 50Cr 4.05Cr 3.97Cr 174.26Cr	P/E 2024	-4.93x	P/E 2025	-9.22x
Enterprise Value	3.22Cr 1.08Cr 94.68L 87.57L 81.74L 1.53Cr 102.39Cr 1.55Cr 10Cr 4.05Cr 50Cr 4.07Cr 3.98Cr 174.88Cr	EV / Sales 2024	376x	EV / Sales 2025	-
Free-Float	54.11%	Yield 2024 *	-	Yield 2025	-

04/05	Y.B Urban Renewal - Residential Development Ltd Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03/05	Y.B Urban Renewal - Residential Development Ltd Auditor Raises 'Going Concern' Doubt	CI
13/11	Y.B Urban Renewal - Residential Development Ltd announced that it expects to receive ILS 0.53001 million in funding	CI
10/25/10	Y.B Urban Renewal - Residential Development Ltd Reports Earnings Results for the Half Year Ended June 30, 2025	CI
01/24/01	Y.B Urban Renewal - Residential Development Ltd Reports Earnings Results for the Half Year Ended June 30, 2024	CI
11/24/11	Cannassure Therapeutics Ltd will Change its Name to Y.B URBAN RENEWAL - RESIDENTIAL DEVELOPMENT LTD	CI
28/24/28	Y.B Urban Renewal - Residential Development Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	CI
27/24/27	Y.B Urban Renewal - Residential Development Ltd Auditor Raises 'Going Concern' Doubt	CI
31/23/31	Cannassure Therapeutics Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	CI
27/23/27	Cannassure Therapeutics Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	CI
09/21/09	Cannassure Was Granted A Patent for an Oral Delivery Method of Cannabis and Cannabinoids Compositions by the Israel Patents Authority	CI

26/21/26	DanCann Pharma A/S : publishes Year-end report for 2020	AQ
18/21/18	Cannassure Therapeutics : DanCann Pharma's strategic partner, Cannassure Therapeutics Ltd., enter exclusive licensing agreement regarding topical medical cannabis products based on Lipidor's AKVANO® technology	AQ
18/21/18	Lipidor : and Cannassure enter exclusive licensing agreement regarding topical medical cannabis products based on Lipidor's AKVANO technology	AQ
15/20/15	DanCann Pharma A/S : enter exclusive agreement with Cannassure Therapeutics to be multinational distributor for Scandinavia (Denmark, Norway, Sweden, and Finland)	AQ
19/20/19	Lipidor : publishes interim report for Q3 2020	AQ

Manager	Title	Age	Since
Ada Bar Kama CEO	Chief Executive Officer	56	31/03/2022
Oren Attiya DFI	Director of Finance/CFO	44	-
Daniel Spira AUD	Comptroller/Controller/Auditor	71	26/06/2019

Director	Title	Age	Since
Nir Peles CHM	Chairman	53	09/12/2021
Shimon Bar-Kama BRD	Director/Board Member	73	04/12/2018
Varda Kalal BRD	Director/Board Member	58	14/02/2022

Cannassure Therapeutics Ltd Share Price TEL AVIV STOCK EXCHANGE

Stocks

CSURE

IL0001110134

Real Estate Development & Operations

Valuation: Cannassure Therapeutics Ltd

Latest news : Cannassure Therapeutics Ltd

Press Releases: Cannassure Therapeutics Ltd

Quotes and Performance

Managers and Directors: Cannassure Therapeutics Ltd

Other Real Estate Development & Operations

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CANNASSURE THERAPEUTICS LTD	-7.54%	-22.20%	-	-	1.08Cr
NFINITI INC.	+252.94%	-99.80%	-99.74%	-	9.55TCr
SUN HUNG KAI PROPERTIES LIMITED	+0.80%	-2.91%	+33.73%	+13.49%	4.17TCr
EMAAR PROPERTIES	-0.46%	+10.26%	+4.03%	+97.55%	3.12TCr
MITSUBISHI ESTATE CO., LTD.	-1.56%	-4.98%	+43.19%	+127.50%	3.03TCr
CHINA RESOURCES LAND LIMITED	-2.81%	-16.36%	+17.22%	-6.79%	2.92TCr
MITSUI FUDOSAN CO., LTD.	-2.05%	-5.10%	+6.44%	+53.00%	2.54TCr
ALPHA DHABI HOLDING	-1.23%	+7.19%	-30.12%	-55.96%	2.22TCr
SUMITOMO REALTY & DEVELOPMENT CO., LTD.	-1.83%	-0.73%	+20.02%	+90.95%	2.07TCr
CK ASSET HOLDINGS LIMITED	+0.13%	-3.37%	+35.72%	+1.87%	1.99TCr
Average	+23.64%	-0.52%	+3.39%	+40.20%	3.51TCr
Weighted average by Cap.	+75.68%	-0.60%	-17.58%	+42.13%

	2024	2025
Net sales	76T 25.54T 22.32T 20.65T 19.27T 36.18T 24.14L 36.44T 2L 95.46T 11.87L 95.91T 93.83T 41.23L	-
Net income	-36.75L -12.35L -10.79L -10L -9L -17.49L -12Cr -17.62L -1.19Cr -46.16L -5.74Cr -46.38L -45.37L -20Cr	-29.96L -10.07L -9L -8L -8L -14.26L -9.52Cr -14.37L -96.72L -37.63L -4.68Cr -37.81L -36.99L -16Cr
Net Debt	10L 3L 3L 3L 2L 5L 3.11Cr 5L 31.64L 12.31L 1.53Cr 12.37L 12.1L 5.32Cr	1L 38.65T 33.77T 31.24T 29.16T 54.74T 36.53L 55.14T 4L 1L 17.96L 1L 1L 62.39L